Summary
The disappearance of cyclobarbital from plasma has been followed in healthy volunteers and in neurological and psychiatric patients after oral administration of one tablet of Phanodorm®, containing cyclobarbital calcium 200 mg. Plasma levels were measured by a thin-layer chromatographic method with in situ densitometry. The average t1/2 in healthy female and male volunteers was 13.3 h, and with the assumption of complete availability a mean distribution coefficient of 0.69 l/kg−1 and a clearance of 40.4 ml/min−1 were calculated. Repeated experiments in seven volunteers revealed good reproducibility of all values. When the healthy volunteers were combined with a group of untreated epileptics, a dependence of t1/2 and of the apparent volume of distribution on age was found, while clearance did not change with increasing age (range 17–54 years). Long half-lives caused by low clearance values were observed in several individuals with moderate obesity. No consistent change in cyclobarbital kinetics followed acute exposure of volunteers to alcohol or on treatment of neurological patients with carbamazepine. Patients under treatment with perazine exhibited more or less normal kinetic values. In terms of drug interaction, cyclobarbital differs from phenazone in several respects, and so it may prove a useful additional substance for measurement of the rate of drug oxidation in humans.
Similar content being viewed by others
References
Andreasen, P.B., Vesell, E.S.: Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration. Clin. Pharmacol. Ther.16, 1059–1065 (1974)
Arnold, W., Grützmacher, H.F.: Die Identifizierung von Barbiturat-Metaboliten mittels Massenspektrometrie und Infrarot-Spektrum. Arch. Toxikol.25, 200–215 (1969)
Breimer, D.D., Winten, M.A.C.M.: Pharmacokinetics and relative bioavailability of cyclobarbital calcium in man after oral administration. Europ. J. clin. Pharmacol.9, 443–450 (1976)
Breyer, U.: Perazine, chlorpromazine and imipramine as inducers of microsomal drug metabolism. Naunyn-Schmiedeberg's Arch. Pharmacol.272, 277–288 (1972)
Breyer, U.: Rapid and accurate determination of the level of carbamazepine in serum by ultraviolet reflectance photometry on thin-layer chromatograms. J. Chromatogr.108, 370–374 (1975)
Breyer, U., Jahns, I., Irmscher, G., Rassner, H., Rehmer, S.: Kinetics of35S-perazine in the bile fistula rat. Naunyn-Schmiedeberg's Arch. Pharmacol.300, 47–56 (1977)
Breyer, U., Villumsen, D.: Thin-layer chromatographic determination of barbiturates and phenytoin in serum and blood. J. Chromatogr.115, 493–500 (1975)
Breyer, U., Villumsen, K.: Measurement of plasma levels of tricyclic psychoactive drugs and their metabolites by UV reflectance photometry of thin layer chromatograms. Europ. J. clin. Pharmacol.9, 457–465 (1976)
Bush, M.T., Weller, W.L.: Metabolic fate of hexobarbital (HB). Drug Metab. Rev.1, 249–290 (1972)
Chung, H., Brown, D.R.: Mechanism of the effect of acute ethanol on hexobarbital metabolism. Biochem. Pharmacol.25, 1613–1616 (1976)
Cinti, D.L., Grundin, R., Orrenius, S.: The effect of ethanol on drug oxidations in vitro and the significance of ethanol-cytochrome P-450 interaction. Biochem. J.134, 367–375 (1973)
Crooks, J., O'Malley, K., Stevenson, I.H.: Pharmacokinetics in the elderly. Clin. Pharmacokin.1, 280–296 (1976)
Ehrnebo, M., Agurell, S., Jalling, B., Boréus, L.O.: Age differences in drug binding by plasma proteins: studies on human fetuses, neonates and adults. Europ. J. clin. Pharmacol.3, 189–193 (1971)
Ehrnebo, M., Odar-Cederlöf, I.: Binding of amobarbital, pentobarbital and diphenylhydantoin to blood cells and plasma proteins in healthy volunteers and uraemic patients. Europ. J. clin. Pharmacol.8, 445–453 (1975)
Fretwurst, F., Halberkann, J., Reiche, F.: Phanodorm und seine Wiederausscheidung mit dem Harn. Münch. med. Wochenschr.79, 1429–1432 (1932)
Gibaldi, M., Boyes, R. N., Feldman, S.: Influence of first-pass effect on availability of drugs on oral administration. J. Pharm. Sci.60, 1338–1340 (1971)
Gundert-Remy, U., Marquardt, R., Andritsch, F., Weber, E.: Veränderungen der Halbwertszeit von Antipyrin und Tolbutamid bei chronischen Alkoholikern im Verlauf der Entziehungstherapie. Inn. Med.2, 67–72 (1975)
Haacke, H., Johnsen, K., Kolenda, K.-D.: Interaction of pentobarbital, diphenylhydantoin and digitoxin with ethanol in isolated perfused guinea-pig liver. Arzneim.-Forsch.26, 835–839 (1976)
Hepner, G. W., Vesell, E. S., Lipton, A., Harvey, H. A., Wilkinson, G. R., Schenker, S.: Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: Diazepam breath test and correlations in drug elimination. J. Lab. Clin. Med.90, 440–456 (1977)
Hvidberg, E. F., Dam, M.: Clinical pharmacokinetics of anticonvulsants. Clin. Pharmacokin.1, 161–188 (1976)
Iber, F. L.: Drug metabolism in heavy consumers of ethyl alcohol. Clin. Pharmacol. Ther.22, 735–742 (1977)
Inaba, T., Kalow, W.: Salivary excretion of amobarbital in man. Clin. Pharmacol. Ther.18, 558–562 (1975)
Inaba, T., Tang, B. K., Endrenyi, L., Kalow, W.: Amobarbital — probe of hepatic drug oxidation in man. Clin. Pharmacol. Ther.20, 439–444 (1976)
Irvine, R. E., Grove, J., Toseland, P. A., Trounce, J. R.: The effect of age on the hydroxylation of amylobarbitone sodium in man. Br. J. clin. Pharmacol.1, 41–43 (1974)
Janke, W., Schmatzer, E.: Experimental-psychologische Untersuchungen zur Wirkung einer Prothipendyl-Cyclobarbital-Calcium-Kombination im Vergleich zu Cyclobarbital-Calcium und Placebo. Arzneim.-Forsch.12, 1031–1036 (1962)
Kadar, D., Inaba, T., Endrenyi, L., Johnson, G. E., Kalow, W.: Comparative drug elimination capacity in man — glutethimide, amobarbital, antipyrine, and sulfinpyrazone. Clin. Pharmacol. Ther.14, 552–560 (1973)
Klotz, U., Avant, G. R., Hoyumpa, A., Schenker, S., Wilkinson, G. R.: The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J. clin. Invest.55, 347–359 (1975)
Leslie, C. A., Gottesfeld, Z., Elliott, A. C.: Effect of ethanol on entry of some substances into the brain of rats. Canad. J. Physiol. Pharmacol.49, 833–840 (1971)
Lieber, C. S., Teschke, R., Hasumura, Y., DeCarli, L. M.: Differences in hepatic and metabolic changes after acute and chronic alcohol consumption. Fed. Proc.34, 2060–2074 (1975)
Machata, G.: Über die gaschromatographische Blutalkoholbestimmung. 2. Mitteilung. Blutalkohol7, 345–348 (1970)
Münch, F. L.: Enzymkinetische Untersuchungen zur mikrosomalen Barbiturat-Hydroxylierung und ihrer Hemmbarkeit durch Äthanol. Thesis, Universität Tübingen 1978
Petruch, F., Schüppel, R. V. A.: Einfluß antikonvulsiver Behandlung auf den Arzneimittelabbau beim Menschen. Induktion des hydroxylierenden Enzymsystems der Leber durch Diphenylhydantoin und Carbamazepin. Bibl. Psychiatr.151, 76–80 (1975)
Petruch, F., Schüppel, R., Breyer, U.: Änderung des Arzneimittelabbaus in der Leber unter der Behandlung mit Perazin. Arzneim.-Forsch.26, 1154–1155 (1976)
Pirttiaho, H. I., Sotaniemi, E. A., Ahlqvist, J., Pitkänen, U., Pelkonen, R. O.: Liver size and indices of drug metabolism in alcoholics. Eur. J. clin. Pharmacol.13, 61–67 (1978)
Reidenberg, M. M.: Obesity and fasting — effects on drug metabolism and drug action in man. Clin. Pharmacol. Ther.22, 729–734 (1977)
Rubin, E., Gang, H., Misra, P. S., Lieber, C. S.: Inhibition of drug metabolism by acute alcohol intoxication. A hepatic microsomal metabolism. Am. J. Med.49, 801–806 (1970)
Sachs, L.: Statistische Auswertungsmethoden. Berlin, Heidelberg, New York: Springer 1968
Schüppel, R. V. A.: Drug metabolism as influenced by ethanol. Pharmacokinetic aspects of drug-ethanol interaction. Excerpta Medica, Int. Congr. Ser.254, 52–62 (1972)
Schüppel, R., Petruch, F.: Mechanism of barbiturate-ethanol interaction. Naunyn-Schmiedeberg's Arch. Pharmacol.270, R129 (1971)
Seidel, G.: Verteilung von Pentobarbital, Barbital und Thiopental unter Äthanol. Naunyn-Schmiedeberg's Arch. exp. Pathol. Pharmakol.257, 221–229 (1967)
Smith, S. E., Rawlins, M. D.: Prediction of drug oxidation rates in man: Lack of correlation with serum gamma-glutamyl trans-peptidase and urinary excretion of D-glucaric acid and 6β-hydroxy cortisol. Eur. J. clin. Pharmacol.7, 71–75 (1974)
Thomas, B. H., Coldwell, B. B., Solomouraj, G., Zeitz, W., Trenholm, H. L.: Effect of ethanol on the fate of pentobarbital in the rat. Biochem. Pharmacol.21, 2605–2614 (1972)
Tilstone, W. J., Reavey, P. C.: Ethanol and the disposition of amylobarbitone: effect of dose and significance as a mechanism for increased toxicity. J. Pharm. Pharmacol.30, 319–320 (1978)
Vajda, F., Williams, F. M., Davidson, S., Falconer, M. A., Brekkenridge, A.: Human brain, cerebrospinal fluid, and plasma concentrations of diphenylhydantoin and phenobarbital. Clin. Pharmacol. Ther.15, 597–603 (1974)
Vesell, E. S., Page, J. G.: Genetic control of dicumarol levels in man. J. clin. Invest.47, 2657–2663 (1968)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Breyer-Pfaff, U., Jerg, H. & Petruch, F. Cyclobarbital as a test substance for oxidative drug metabolism in man. Findings in neuropsychiatric patients. Eur J Clin Pharmacol 15, 433–441 (1979). https://doi.org/10.1007/BF00561744
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00561744